Jaffer A. Ajani, MD, MD Anderson Cancer Center

A brief discussion regarding current data and interest in treating appropriate patients with metastatic colorectal cancer with potent KRAS G12C selective inhibitors.

Drs Jaffer A. Ajani and Zev A. Wainberg comment on current obstacles surrounding the treatment of metastatic colorectal cancer and consider the future use of ctDNA as more is learned about the disease.

Best practices for managing skin rashes associated with anti-EGFR therapy for metastatic colorectal cancer.

Recommendations for treating patients with relapsed/refractory metastatic colorectal cancer in the third-line or later settings with regorafenib or TAS-102 therapy.

The importance of aligning second-line treatment decisions with patient goals in metastatic colorectal cancer, and the benefits of treating patients with biweekly cetuximab, especially during the COVID-19 pandemic.

Reactions to recent changes approved by the FDA to the dosing schedule of cetuximab for metastatic colorectal cancer and the value of real-word data on clinical practice patterns in the community when administering this drug.

Treatment approaches available for patients with newly diagnosed metastatic colorectal cancer that is RAS wild type and factors that impact decisions for utilizing a 2-drug versus 3-drug regimen.

Drs Jaffer A. Ajani and Zev A. Wainberg comment on the rationale for conducting full next-generation sequencing panels on patients with metastatic colorectal cancer and explain how to best utilize information provided to inform treatment decisions.

The significance of studying genomics in metastatic colorectal cancer and an overview of actionable targets that can be tested for to help in treatment decisions for newly diagnosed disease.

Dr Jaffer A. Ajani highlights the increasing incidence of colorectal cancer diagnoses in younger patients as a growing concern during a discussion on trends in prevalence.

Jaffer A. Ajani, MD, discusses the potential clinical implications of fam-trastuzumab deruxtecan-nxki in gastric or gastroesophageal junction adenocarcinoma if approved by the FDA.